Clinical Trial: A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07807241) titled 'A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3' on Aug. 26.

Brief Summary: This is a Phase 1a/1b, multicenter, open-label, first-in-human (FIH) study with MX006 treatment in patients with selected tumor types known to express B7-H3. The study will include 2 parts:

* Dose-escalation (Part A)

* Dose-expansion (Part B) A maximum of 120 patients may be enrolled in this study. The primary objective of the dose escalation (PART A) is to evaluate the safety and tolerability of MX006 and determine the maximum-tolerated dose (MTD) and the recommended doses for expansion (RDE) in patients with sel...